Institute for Life Science Entrepreneurship supports startups and entrepreneurs in the life sciences sector with research, development, and business support. It is self-described as a 501(c)(3) not-for-profit organization.

Institute for Life Science Entrepreneurship

Institute For Life Science Entrepreneurship (ILSE) | 833 followers on LinkedIn. ILSE is a research institute, accelerator and incubator facilitating translation of early innovation into successful Tx. | The Institute for Life Science Entrepreneurship (ILSE) is a newly formed organization structured to become a uniquely effective model for academic, industry, and entrepreneurial collaboration.  The Institute&#39;s mission is to catalyze and accelerate the translation of breakthrough discoveries in the life sciences into safe and effective pharmaceutical, biological, medical device and biotechnology products.  It has been designed to link together time-critical resources on a large scale from a broad spectrum of disciplines and players in academia and industry to advance innovation, creativity and entrepreneurism (ICE) in the life sciences.

Keith Bostian

President at Institute For Life Science Entrepreneurship (ILSE) Founder and CEO, Plumeria Therapeutics, Inc.

Thomas P. Richardson PhD, MBA

Chairman of Advisory Council at Institute of Life Science Entrepreneurship

Rashmi Barbhaiya

Senior Vice President, Head of Real-World Data Product Strategy

Bill Hanlon

Institute For Life Science Entrepreneurship (ILSE)

CARB-X 2024 Funding Round The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced funding solicitation with four distinct product themes: THERAPEUTICS FOR INFECTIONS CAUSED BY GRAM-NEGATIVE PATHOGENS The scope is restricted to direct-acting small-molecule therapeutics. Molecules with properties that will deliver an IV route with an oral stepdown are preferred. In all cases, activity against both susceptible and multidrug-resistant organisms on the WHO and CDC bacterial threat lists is essential. PREVENTION FOR INVASIVE DISEASE Novel approaches to prevention of invasive disease caused by Staphylococcus aureus or Escherichia coli are sought. Given the history of challenges in drug development in this arena, modalities other than vaccines are preferred; however, if a vaccine is proposed, a novel aspect (e.g. adjuvant strategy or vaccine composition) that makes a compelling case must be underscored. DIAGNOSTICS FOR NEONATAL SEPSIS Consistent with CARB-X “Aligned by Design” strategy, they seek diagnostics to support the growing portfolio of potential maternal vaccines to prevent neonatal sepsis. Products focused on rapid triage, bacterial identification and/or automated susceptibility testing are sought. Time-to-result and cost-of-goods are key criteria, and small-sample volumes are critical for this patient population. Pathogen ID and AST Products must focus on priority pathogens, including Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus and Acinetobacter baumannii. PROOF-OF-CONCEPT FOR NOVEL SAMPLE TYPES FOR DIAGNOSING LOWER-RESPIRATORY-TRACT INFECTIONS Consistent with our “Aligned by Design” strategy, we seek diagnostics to support the many therapeutic projects focused on lower-respiratory-tract infections (LRTI). Owing to the challenges with BAL samples, as a first step, projects that can demonstrate proof-of-concept data with novel sample types are sought. Target product profiles and minimal acceptable criteria for all funding calls will be defined and available on carb-x.org . Expressions of interest for all themes may be submitted during these timeframes: 18 March 2024 at 10:00 ET – 29 March 2024 at 23:59 ET 23 September 2024 at 10:00 ET – 4 October 2024 at 23:59 ET Further details are available at CARB-X.org website

ILSE

COM:ILSEBIO

Institute for Life Science Entrepreneurship